



**Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

February 20, 2024: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)
- **DVHA Pharmacy Administration Updates** **6:35 - 6:50**
- **Chief Medical Officer Updates** **6:50 - 6:55**
- **Follow-up Items from Previous Meetings** **6:55 – 7:00**
 - Flovent[®] HFA (fluticasone propionate) Discontinuation
- **RetroDUR/ProDUR** **7:00- 7:25**
 - Follow-Up: Co-prescribing of Opioids, Benzodiazepines, and Muscle Relaxants
 - Data presentation: GLP-1 Receptor Agonist Adherence
 - Introduce The Effect of Hemlibra[®] (Emicizumab-kxwh) on the Cost of Care in Hemophilia A Patients
- **Clinical Update: Drug Reviews** **7:25-7:45**
(Public comment prior to Board action)
 - **Biosimilar Drug Reviews**
 - None at this time.
 - **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Elevidys[®] (delandistrogene moxeparvovec-rokl)
 - Ngenla[™] (somatrogon-ghla)
 - Opvee[®] (nalmefene)
 - Roctavian[™] (valoctocogene roxaparvovec- rvox)
 - Skyclarys[™] (omaveloxolone)
 - Sulfave[™] (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution)
 - Vyjuvek[®] (beremagene geperpavec-svdt)
 - Vyvgart Hytrulo[®] (efgartigimod alfa-fcab)
- **New Managed Therapeutic Drug Classes** **7:45 -7:45**
 - None at this time.

- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:25**
(Public comment prior to Board action)
 - Antibiotics: GI & Related
 - Antibiotics: Cephalosporins
 - Antibiotics: Fluoroquinolones
 - Antibiotics: Macrolides
 - Antibiotics: Tetracyclines
 - Antivirals: Oral
 - Antivirals: Topical (New Drug Ycanth™ (cantharidin) included in TCR)
 - Skeletal Muscle Relaxants
 - Antiretrovirals

- **Review of Newly Developed/Revised Criteria** **8:25 - 8:25**
(Public comment prior to Board action)
 - None at this time.

- **General Announcements** **8:25 – 8:30**
 - FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
<https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr>

- **Adjourn** **8:30**